{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056254","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.465661+00:00","generated_at":"2026-06-02T06:18:19.657753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M","bullets":["Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.","Net product revenue $88.6M, up 24% YoY; includes $110.5M non-cash inventory write-down due to product withdrawal.","Voluntarily discontinuing RELYVRIO/ALBRIOZA for ALS; existing patients transitioned to free drug program.","Cash $373.3M, expected runway into 2026; interim HELIOS Wolfram data show improvement; topline from 12 patients expected fall 2024.","Phase 3 ORION PSP trial data expected mid-2025; IND and clinical trial of AMX0114 in ALS planned for H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056254","json":"https://secwatch.observer/filing/0000950170-24-056254.json","markdown":"https://secwatch.observer/filing/0000950170-24-056254.md","text":"https://secwatch.observer/filing/0000950170-24-056254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/0000950170-24-056254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/amlx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:18:19.657753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aee4b330212c681ed5bdb3405187bab311607e6e","claim":"Amylyx Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/0000950170-24-056254-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}